Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Recursion Pharmaceuticals, Inc. (RXRX) has a Wall Street consensus price target of $11.00, based on estimates from 10 covering analysts. With the stock currently trading at $3.67, this represents a potential upside of +199.7%. The company has a market capitalization of $1.94B.
Analyst price targets range from a low of $11.00 to a high of $11.00, representing a 0% spread in expectations. The median target of $11.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, RXRX trades at a trailing P/E of -2.5x. Analysts expect EPS to grow +19.9% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RXRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for RXRX is $11, representing 199.7% upside from the current price of $3.67. With 10 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
RXRX has a consensus rating of "Hold" based on 10 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $11 implies 199.7% upside from current levels.
RXRX's current price is $3.67 with a consensus target of $11 (199.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $11 for RXRX, while the most conservative target is $11. The consensus of $11 represents the median expectation. These targets typically reflect 12-month expectations.
RXRX is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RXRX stock forecast based on 10 Wall Street analysts shows a consensus price target of $11, with estimates ranging from $11 (bear case) to $11 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on RXRX, with a "Hold" consensus rating and $11 price target (199.7% upside). 4 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RXRX analyst price targets range from $11 to $11, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11 consensus represents the middle ground.